Your cart is currently empty!
8 Results
$1.7M NIH SBIR Phase II Grant Awarded to AlphaThera for Development of ADCs to target Pancreatic Cancer
AlphaThera was awarded an SBIR Phase II grant by the NIH/NCI to further development of ADCs generated by proximity-based sortase-mediated ligation.
Supplemental $50,000 NIH TABA funding awarded to AlphaThera to support scaled commercialization of Site-specific Antibody Labeling Technology
The TABA supplemental funding will go directly towards supporting scaled commercialization activities of AlphaThera’s site-specific antibody labeling technology.
AlphaThera Awarded $667,000 SBIR Phase II Grant Extension for COVID-19 Detection Products
AlphaThera was awarded a grant to research & commercialize conjugation technologies that will assist in scale-up of COVID-19 serological assays to meet demand for daily testing.
NIH Grant Awarded to AlphaThera for Targeted Degradation of Cytosolic Proteins
AlphaThera was awarded an NIH Grant for research into Trim21-mediated degradation of antibody-targeted cytosolic proteins.
NIH Grant Awarded to AlphaThera for Antibody-MNase Conjugation
AlphaThera was awarded an NHI/NHLBI Grant to fund research for Photoreactive Antibody-Binding Domain-Microccocal Nuclease Conjugates ((pAbBD)-MNase).
NIH Phase II Grant to AlphaThera for Antibody Site-Specific Immobilization & Labeling
AlphaThera was awarded an NIH Phase II Grant for continued research into site-specific labeling and immobilization of antibodies for immunoassays.
NIH Grant Awarded to AlphaThera for Site-Specific ADCs by PBSL
AlphaThera awarded a grant by the NIH/NCI to fund research for Site-specific Antibody-Drug Conjugates by proximity-based sortase ligation.
NIH Grant Awarded to AlphaThera for Site-Specific Antibody Immobilization for Immunoassays Grant Award
AlphaThera was awarded an NIH/NIBIB Grant to fund research for designing Tools for Site-Specific Antibody Immobilization for Immunoassays.
5 Results
AlphaThera relocates to accommodate the company’s rapid expansion
AlphaThera have announced their relocation to a new larger laboratory and office space within the Pennovation Works Lab Building at the University of Pennsylvania.
AlphaThera Interview: Penn Center for Innovation interviews co-founder Dr. Andrew Tsourkas
AlphaThera’s co-founder, Dr. Andrew Tsourkas, was featured in a speaker event “Moving Ideas to Market: A Discussion with Entrepreneurs & Researchers” hosted by Penn Center for Innovation
AlphaThera in the News: oYo-Link™ Oligo Product Spotlight with Pennovation Center
Pennovation Works featured a product spotlight for AlphaThera’s oYo-Link™ Oligo Custom conjugation product.
AlphaThera Interview: Colliers LabNotes interviews AlphaThera co-founder Dr. Andrew Tsourkas
Joe Fetterman of Colliers LabNotes interviews AlphaThera co-founder Dr. Andrew Tsourkas about his backstory & path toward founding AlphaThera.
AlphaThera in the News: The Daily Pennsylvanian
UPenn’s prominent independent newspaper, the Daily Pennsylvanian, featured an article about AlphaThera’s recent COVID-19 grant award.
3 Results
Expansion of AlphaThera’s Distributor Network supports worldwide delivery of oYo-Link Antibody Labeling Technology
AlphaThera has announced the further expansion of its distributor network as interest in their oYo-Link Site Specific Antibody Labeling Technology continues to grow on an international scale.
oYo-Link® Products Now Available to Purchase through Quartzy
AlphaThera has teamed up with Quartzy to make their oYo-Link Antibody labeling products conveniently available to researchers for purchase.
Funakoshi Co., Ltd. Announced as AlphaThera’s Distribution Partner in Japan
AlphaThera has announced a distribution agreement with Funakoshi Co., Ltd. to deliver oYo-Link® Antibody labeling products to researchers in Japan.
4 Results
AlphaThera announces the launch of oYo-Capture™ Magnetic Beads
For the efficient removal of free oYo-Link® post conjugation AlphaThera has announced the launch of oYo-Capture™ Magnetic Beads, providing researchers with an efficient method of removing free oYo-Link® reagents post antibody conjugation to ensure low background in high sensitivity assays. AlphaThera is well known within the life science research community for their oYo-Link® antibody labeling […]
AlphaThera launches oYo-Link® Horseradish Peroxidase (HRP)
AlphaThera has announced the launch of oYo-Link® Horseradish Peroxidase (HRP), the latest addition to their range of site-specific antibody labeling reagents. The oYo-Link antibody-HRP labeling technology will enable the rapid production of highly uniform primary antibody conjugates in under two hours, and with only 30 seconds hands-on time.
AlphaThera Expand Their Range of oYo-Link Antibody-Drug Conjugate Reagents
AlphaThera have announced the addition of DM4 to their range of oYo-Link® Antibody-Drug Conjugation Reagents which also includes VcMMAE, VcMMAF and DM1.
AlphaThera Launches oYo-Link® Epitope Tag for Enhanced Multiplexing Capability
AlphaThera has announced the launch of oYo-Link® Epitope Tag, the latest addition to their range of site-specific antibody labeling reagents.
4 Results
AlphaThera Highlighted in Nature Methods Article: “How single-cell multi-omics builds relationships”
Dr. Andrew Tsourkas and Dr. Feifan Yu interview about oYo-Link Oligo technology and its potential within the field of multi-omic single-cell analysis.
AlphaThera & Penn Researchers’ Publication: Efficient native IgG labeling for ADC Production
AlphaThera members & Penn researchers worked to publish a high-impact publication in Bioconjugate Chemistry titled “Efficient Labeling of Native Human IgG by Proximity-Based Sortase-Mediated Isopeptide Ligation”.
Publication Feature: “Targeting cartilage EGFR pathway for osteoarthritis treatment” Science Translational Medicine
Read how a research team used AlphaThera’s site-specific bioconjugation technique to seed nanoparticles with a TGFa payload.
AlphaThera in the News: Atlas of Science
A layman’s summary of AlphaThera’s LASIC site-specific Antibody labeling technology was published by the Atlas of Science.